Cardiogen 20mg

▎ Cardiogen Hoʻokumu

▎ i ka naʻau Noiʻi ʻana

He aha ke kumu noiʻi o Cardiogen?  

Hoʻoikaika ʻia e nā pono o ka pale ʻana i ka maʻi maʻi / mālama ʻana a me ka maʻi maʻi cardiovascular, ua loaʻa i ka noiʻi ma Cardiogen ka nānā nui ʻana. Ua ʻike nā mea noiʻi ʻo Cardiogen peptide ke kāohi i ka transplantable M-1 sarcoma, hoʻoulu i ka apoptosis cell tumor a me ka hemorrhagic necrosis, e hāʻawi ana i kahi kuhikuhi hou no ka mālama ʻana i ka maʻi maʻi. Eia nō naʻe, ʻo kona waiwai kūpono i ka hoʻoponopono ʻana i nā helu physiological cardiac a me ka hoʻoulu ʻana i ka myocardial regeneration ua lawe mai i nā manawa hou no ka noiʻi ʻana i ka maʻi cardiovascular.  

Me ka piʻi ʻana o ka hoʻomohala ʻana i ka lāʻau lapaʻau bioactive peptide, ʻo ke aʻo ʻana i ka hoʻolālā a me ka hana o Cardiogen he mea koʻikoʻi loa ia ma ke ʻano he peptide biologically active me nā waiwai kūʻokoʻa. ʻO ka hoʻomohala ʻana i nā ʻenehana e like me ka genetic engineering a me proteomics ua hāʻawi i ke kākoʻo ʻenehana no ka ʻimi hohonu ʻana i ke kumu o Cardiogen a me ka wehewehe ʻana i kāna ʻano hana, e alakaʻi i ka noiʻi pili i mua.  

He aha ke ʻano o ka hana o Cardiogen?

ʻO ka hoʻokomo ʻana o ka Tumor Cell Apoptosis: Hōʻike nā haʻawina ma hope o ka hoʻokomo ʻana i ka Cardiogen i nā ʻiole me ka M-1 sarcoma hiki ke hoʻololi ʻia, ʻoi aku ka kiʻekiʻe o ke kiʻekiʻe o ka apoptosis cell tumo ma nā pūʻulu hoʻokolohua āpau ma mua o kēlā ma ka pūʻulu mana. Hōʻike kēia e hiki i ka Cardiogen ke hoʻoulu i nā hana apoptosis i loko o nā pūnaewele maʻi ma o kekahi mau ala, e koi ana i nā cell tumor e hele i ka make cell programmed. ʻO ka Apoptosis kahi kaʻina hana e hoʻopau ai nā cell i ko lākou ola ma hope o kā lākou papahana ponoʻī ma lalo o kekahi mau kūlana physiological a pathological paha. ʻO ka maʻamau, hoʻoponopono pololei ʻia ka apoptosis e nā ʻano genes a me nā ala hōʻailona. Hiki i ka Cardiogen ke hoʻoikaika i nā genes pili i ka apoptosis a i ʻole nā ala hōʻailona, ​​e like me ka hana ʻana i nā protein ʻohana Bcl-2 e hoʻonui i ka hōʻike ʻana o nā protein pro-apoptotic (eg, Bax) a i ʻole ke kāohi i ka hana o nā protein anti-apoptotic (eg, Bcl-2), a laila e hoʻoulu ai i ka hoʻokuʻu ʻana o ka cytochrome C mai ka mitochondria e alakaʻi ana i ka cytoplasm a me ka hopena hope loa. apoptosis ^[1] .

Kiʻi 1. Nā hana epigenetic i nā maʻi cardiovascular. Hoʻopili ka puʻuwai (waena) i ʻekolu mau mea hoʻoponopono epigenetic nui e hoʻopiʻi ana i ka pathophysiology cardiovascular.

Puna:MDPI ^[5]

ʻO ka hoʻokomo ʻana i ka maʻi maʻi maʻi puʻupuʻu: ʻO ka hoʻopaʻa ʻana i ka nui o ka ulu ʻana o ka sarcoma M-1 ma hope o ka hoʻokele Cardiogen ma muli o ka necrosis hemorrhagic tumor. Ke hilinaʻi nei ka ulu ʻana o ka tumor i ka neovascularization no nā meaʻai a me ka oxygen. Hiki i ka Cardiogen ke hoʻokō i kēia hopena ma ka hoʻopili ʻana i ka hana maʻamau o ka ʻupena vascular tumor. Hiki iā ia ke hana i nā pūnaewele endothelial vascular, e hoʻopilikia i ka hōʻailona o nā mea pili i ka angiogenesis (e like me ka vascular endothelial growth factor VEGF), e hoʻopau i ka hoʻonui ʻana, neʻe, a me ka hiki ke hoʻokumu lumen o nā pūnaeho endothelial vascular, e alakaʻi ana i ka angiogenesis tumo impaired, ischemia kūloko, a me ka hypoxia i ka ʻiʻo neʻe koko. I ka manawa like, hiki iā ia ke hōʻino pololei i nā kīʻaha koko koko, e hoʻoheheʻe ai i ke koko a me ke koko, e hoʻonui hou i ka necrosis tissue tumor ^[1].

ʻAʻole-Direct Cytostatic Effect: Mai ka hiʻohiʻona o nā ʻāpana hana hoʻonui, ʻaʻole i hoʻokumu ʻia ka pale ʻana i ka ulu ʻana o ka maʻi ma muli o ka hopena cytostatic pololei o Cardiogen ma nā cell tumor. ʻO ia ke ʻano, ʻaʻole ia e kaohi pololei i nā kaʻina metabolic maʻamau e like me ka synthesis DNA cell tumor a i ʻole synthesis protein e like me nā lāʻau cytotoxic kuʻuna e pale ai i ka hoʻonui ʻana o ka cell tumor. Akā, pale ia i ka ulu ʻana o ka maʻi maʻi ma o nā hana indirect e like me ka hoʻoulu ʻana i ka apoptosis a me ka hoʻoulu ʻana i ka necrosis hemorrhagic tumor. ʻO kēia hiʻohiʻona o ka hana cytostatic pololei ʻole hiki ke hoʻolilo iā Cardiogen i mea palekana me ka haʻahaʻa haʻahaʻa o ka ʻona i nā cell maʻamau i ka wā e hana ana i nā hopena anti-tumor ^[1].  

Ka Hana Ma o Tumor Vascular Network: Hōʻike nā hōʻike Morphological e pili ana ka hana a Cardiogen i kahi mīkini kikoʻī ma o ka pūnaewele vascular tumor. ʻAʻole hāʻawi wale ka ʻupena vascular tumor i nā meaʻai no nā cell tumor akā he hana koʻikoʻi nō hoʻi i ka metastasis tumor a me nā kaʻina hana ʻē aʻe. Hiki i ka Cardiogen ke hoʻopaʻa i nā mea loaʻa kikoʻī ma ka ʻili o nā cell (e like me nā cell endothelial a me pericytes) i loko o ka ʻupena vascular tumor, e hoʻāla ana i nā ala transduction hōʻailona intracellular a hoʻoulu i kahi ʻano o nā hopena olaola, e like me ka hoʻoponopono ʻana i ka permeability vascular a me ka hoʻoulu ʻana i ka ʻoki a me ka hoʻomaha ʻana o nā ʻiʻo ʻiʻo maʻemaʻe vascular, a laila e hoʻopiʻi ai i nā kaʻina hana tumora a me ka ulu ʻana o ka microenpop.

Hoʻohui ʻia, ʻo ka hana ʻino a me ka hana o ka ʻupena vascular tumor kahi kumu no ka hana i manaʻo ʻia e Cardiogen, hiki iā ia ke hana maʻamau i nā ʻiʻo tumo me ka hopena liʻiliʻi i nā kīʻaha koko maʻamau ^[1]  

He aha nā hoʻohana o Cardiogen?  

Nā hopena ma nā ʻano helu pili puʻuwai: Ma lalo o nā kūlana koʻikoʻi, he kuleana koʻikoʻi ka Cardiogen i ka hoʻoponopono ʻana i ka nui o ka puʻuwai a me nā ʻāpana kaumaha o nā ʻiole. Ua hōʻike ʻia nā haʻawina e hiki ke hoʻopiʻi ʻo Cardiogen i ka hopena o ke koʻikoʻi o ka adrenaline i nā loli nui o ka puʻuwai, nā ʻāʻī adrenal, a me ka spleen, e hoʻomaʻamaʻa i ka nui o kēia mau kino. I ka manawa like, kōkua ia e hōʻemi i ka puʻuwai puʻuwai e kāohi i nā waiwai a hoʻohaʻahaʻa i nā hōʻike o ka arrhythmia ma lalo o ke kaumaha. Hōʻike kēia i hiki iā Cardiogen ke mālama i ke kūlana physiological maʻamau o ka puʻuwai a me nā ʻāpana pili i nā wahi pilikia, e kōkua maikaʻi ana i ka hoʻopaʻa ʻana i ka ʻōnaehana cardiovascular ^[2].  

Nā noi no ka mālama ʻana i nā maʻi naʻau  

ʻO ka mālama ʻana i ka Myocardial Infarction: Cardiogenin, kahi mea hana i hoʻokaʻawale ʻia mai nā mea kanu mea kanu (pili paha me Cardiogen a i ʻole kekahi o kāna mau mea hana), ua hōʻike i ka mana nui i nā ʻano holoholona o ka myocardial infarction. Ua ʻike nā haʻawina e hiki i ka cardiogenin ke hoʻoponopono maikaʻi i nā puʻuwai infarcted, me ka endogenous mesenchymal stem cell (MSCs) i ʻike ʻia e hoʻokaʻawale i nā cardiomyocytes hou i loko o ka wahi infarcted, me ka hoʻomaikaʻi nui ʻana i ka hana cardiac. 

ʻO ka hoʻololi ʻana i nā MSC i mālama mua ʻia me ka EGJ (kahi mea kanu i loaʻa ka cardiogenin) a i ʻole cardiogenin i loko o nā kumu hoʻohālike holoholona myocardial infarction e paipai ana i ka hoʻōla hou ʻana o ka myocardium hana. Hōʻike kēia ʻaʻole hiki i ka cardiogenin ke hoʻoikaika i ka hoʻōla hou ʻana o ka myocardial akā hiki ke hoʻōla i nā MSC, e hāʻawi ana i nā kūlana kūpono no ka hoʻōla hou ʻana o ka myocardial a wehe i nā ala hou no ka mālama ʻana i ka myocardial infarction. Eia kekahi, ua hōʻike ʻia ka hoʻokele waha o ka cardiogenin i nā hopena therapeutic koʻikoʻi ma ka myocardial infarction, me nā MSC endogenous i loaʻa i ka iwi iwi i hoʻopaʻa ʻia ʻo ia ke kumu cell cell no regenerated myocardium. Hōʻike nā haʻawina mechanistic mua e pili ana ka miR-9 a me kāna pahuhopu E-cadherin i ka hoʻokumu ʻana i nā disc intercalated ^{[3, 4]}.  

Nā noi no ka Lapaʻau ʻana i ka maʻi maʻi: Cardiogen peptide e hōʻike ana i nā hopena hoʻololi ʻana i nā ʻiole me ka M-1 sarcoma i hoʻololi ʻia. Ua hōʻike ʻia nā haʻawina ma hope o ka hoʻokele Cardiogen, ʻoi aku ka kiʻekiʻe o ke kiʻekiʻe o ka apoptosis cell tumo ma nā pūʻulu hoʻokolohua āpau ma mua o ka hui hoʻomalu, a ua kāohi ka lāʻau lapaʻau i ka ulu ʻana o ka sarcoma M-1 ma ke ʻano pili. ʻAʻole loaʻa kēia hopena pale mai ka hana cytostatic pololei o ka lāʻau i nā ʻōpū akā mai ka hoʻoulu ʻana i ka necrosis hemorrhagic tumor a me ka hoʻoulu ʻana i ka apoptosis cell tumor. Ma ka morphologically, hiki i ka Cardiogen ke hoʻohana i kāna hana kikoʻī o ka hana ma o ka pūnaewele vascular tumor, e hāʻawi ana i kahi hoʻolālā hou no ka mālama ʻana i ka maʻi kanesa ma o ka hoʻoponopono ʻana i ka microenvironment tumor a me ka hoʻoulu ʻana i ka apoptosis cell tumor ^{[3, 4]}.  

Ka hopena  

I ka hōʻuluʻulu ʻana, hiki i ka Cardiogen ke hoʻoponopono i ka ʻōnaehana cardiovascular, hoʻomaikaʻi i ka hana o ka puʻuwai a me nā ʻāpana pili i lalo o ke kaumaha, a hoʻoikaika i ka hoʻoponopono ʻana i ka myocardial infarction. I kēia manawa, hiki i kāna ʻano peptide ke hoʻoulu i ka apoptosis cell tumor, hoʻoulu i ka hemorrhagic necrosis, a keʻakeʻa i ka ulu ʻana o ka maʻi, e hāʻawi ana i nā kuhikuhi hou no ka mālama ʻana i nā maʻi.

No ka mea kakau

ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.

Mea kākau moʻolelo ʻepekema

He haumana kaulana ʻo Cheng, Lei me ka ʻike noiʻi nui i ka ʻepekema ola a me ka ʻepekema waiwai. Hoʻopili ʻia me nā hui hanohano e like me Hong Kong Polytechnic University, Dali University, a me Chinese University of Hong Kong, ua hōʻike ʻo ia i kahi ʻano aʻoaʻo like ʻole a hohonu. ʻO kāna noiʻi ʻana ma waena o Biochemistry & Molecular Biology, Cell Biology, a me Materials Science, aia ma ke alo o ka noiʻi ʻepekema hou a paʻa i ka mana noi nui. ʻAʻole kā Cheng, Lei wale nō ka hana ʻana i ka ʻimi ʻepekema kumu akā i ka hoʻohui ʻana o ka ʻepekema a me ka ʻenehana, e hāʻawi ana i ke kākoʻo paʻa no ka hoʻomohala ʻana i ka manaʻo a me ka hana ʻenehana i nā kahua pili. ʻO kāna mau hoʻoikaika pū ʻana me nā ʻoihana hoʻonaʻauao like ʻole i mea kōkua i ka hoʻoikaika ʻana i ka hoʻololi hoʻonaʻauao a me ka hui noiʻi.

▎ Nā ʻōlelo pili

[1] Levdik NV, Knyazkin I V. Tumor-hoʻololi i ka hopena o ka cardiogen peptide ma M-1 sarcoma i nā ʻiole senescent [J]. Bulletin of Experimental Biology and Medicine, 2009,148(3):433-436.DOI:10.1007/s10517-010-0730-9.

[2] Mendzheritckiy AM, Vovk AN, Isachkina NS, et al. Ka hopena o ka cardiogen injection i ka adrenaline-induced stress model ma ka helu o ka helu helu puʻuwai a me nā ʻāpana kaumaha o nā kino ʻiole [M]. 2020: 35-37.10.23947/interagro.2020.2.35-37.

[3] ʻO Cheng L, Chen H, Yao X, et al. He laau lapaau no ka hooponopono ana i ka puuwai infarcted[J]. PLoS One, 2009,4(2):e4461.DOI:10.1371/journal.pone.0004461.

[4] Lin X, Peng P, Cheng L, a me al. ʻO kahi hui kūlohelohe i hoʻokomo i ka cardiogenic differentiation o endogenous MSCs no ka hoʻoponopono ʻana i ka naʻau infarcted [J]. Hoʻokaʻawale, 2012,83(1):1-9.DOI:10.1016/j.diff.2011.09.001.

[5] Martínez-Iglesias O, Naidoo V, Carrera I, et al. Nā Huaola Kūlohelohe me nā ʻano Epigenetic no ka mālama ʻana i nā maʻi maʻi cardiovascular [J]. Genes, 2025,16(5}, ARTICLE-NUMBER= {566).DOI:10.3390/genes16050566.

ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.  

ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a i ʻole maʻi. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.